Mastocytosis: Clinical Trials

47 trials for Mastocytosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28 completed, 6 terminated, 5 unknown, 3 active not recruiting. 47 Phase 2, 6 Phase 1, 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 247Completed 28, Terminated 6, Unknown 5, Active not recruiting 3, Recruiting 2, Withdrawn 2, Not yet recruiting 1
Phase 16Completed 4, Terminated 1, Withdrawn 1
Phase 35Completed 2, Unknown 2, Recruiting 1

Follow Mastocytosis: new trials by email Literature Review of Mastocytosis trials Research Report on Mastocytosis

Trials (filtered) newest first · largest first

All 47 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2Not yet recruitingFred Hutchinson Cancer Center522027-01-012026-09-14
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets - SSM, Mastocytosis, Indolent
Phase 2Active not recruitingCogent Biosciences, Inc.2372022-06-272026-10-22
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Elenestinib, Placebo - Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Phase 2 / Phase 3RecruitingBlueprint Medicines Corporation5342021-11-302026-10-07
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
bezuclastinib - Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN)
Phase 2RecruitingCogent Biosciences, Inc.1402021-11-092026-09-15
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients
Hydroxychloroquine - Mastocytosis
Phase 2 / Phase 3UnknownUniversity Hospital, Toulouse302021-10-012021-10-20
Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis
Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base. - Cutaneous Mastocytoses
Phase 2TerminatedJoseph Butterfield12021-07-262024-04-25
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo - SARS-CoV Infection, COVID-19
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)7462021-04-072025-08-12
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
TL-895, Placebo - Myelofibrosis, Indolent Systemic Mastocytosis
Phase 2UnknownTelios Pharma, Inc.1212020-10-222024-05-10
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2WithdrawnCity of Hope Medical Center2020-10-202020-12-17
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Phase 1 / Phase 2TerminatedGT Biopharma, Inc.122020-01-012022-11-10
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Total-Body Irradiation, Thiotepa, Fludarabine - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2Active not recruitingFred Hutchinson Cancer Center452019-08-292026-09-25
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
sarilumab, Placebo - Indolent Systemic Mastocytosis
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)212019-06-192024-12-17
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Avapritinib, Placebo - Indolent Systemic Mastocytosis
Phase 2Active not recruitingBlueprint Medicines Corporation2512019-04-162026-10-02
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Avapritinib - Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis
Phase 2CompletedBlueprint Medicines Corporation1072018-11-212026-10-20
Treatment of Indolent Systemic Mastocytosis With PA101
PA101, Placebo - Mastocytosis, Systemic Mastocytosis
Phase 2CompletedPatara Pharma412015-06-012016-09-29
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Ibrutinib - Aggressive Systemic Mastocytosis, Mast Cell Leukemia
Phase 2TerminatedJason Robert Gotlib42015-03-012018-09-20
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Brentuximab vedotin - Aggressive Systemic Mastocytosis, Mast Cell Leukemia
Phase 2CompletedJason Robert Gotlib102013-09-012019-01-29
Midostaurin in Indolent Systemic Mastocytosis
Midostaurin, - Indolent Systemic Mastocytosis
Phase 2UnknownUniversity Medical Center Groningen202013-08-012015-01-19
Cromoglicate in Mastocytosis
Cromoglicate, Placebo - Mastocytosis
Phase 2TerminatedLEO Pharma72012-10-012025-02-24
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Cladribine and pegylated interpheron alpha-2a - Systemic Mastocytosis
Phase 2 / Phase 3UnknownHospital Virgen de la Salud102012-05-012016-08-29

Showing 20 of 47. Sign in to see all of them.

Narrower conditions

Mastocytosis, Systemic (22)  ·  Leukemia, Mast-Cell (21)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (14)  ·  Leukemia, Myeloid, Acute (13)  ·  Leukemia, Biphenotypic, Acute (11)  ·  Leukemia, Myelomonocytic, Chronic (11)  ·  Leukemia (10)  ·  Burkitt Lymphoma (9)  ·  Hodgkin Disease (9)  ·  Leukemia, Hairy Cell (9)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (9)  ·  Multiple Myeloma (9)  ·  Myeloproliferative Disorders (9)  ·  Lymphoma, B-Cell, Marginal Zone (8)

Broader conditions

Neoplasms by Histologic Type (47)  ·  Mast Cell Activation Disorders (46)  ·  Neoplasms (46)  ·  Immune System Diseases (45)  ·  Neoplasms, Connective and Soft Tissue (35)  ·  Neoplasms, Connective Tissue (34)  ·  Hemic and Lymphatic Diseases (29)  ·  Hematologic Diseases (27)  ·  Leukemia, Myeloid (24)  ·  Bone Marrow Diseases (19)  ·  Leukemia (17)  ·  Chronic Disease (16)  ·  Disease Attributes (16)  ·  Immunoproliferative Disorders (16)

Interventions

Whole-Body Irradiation (5)  ·  fludarabine phosphate (5)  ·  Mycophenolic Acid (4)  ·  Busulfan (3)  ·  Cyclophosphamide (3)  ·  Cyclosporine (3)  ·  Peripheral Blood Stem Cell Transplantation (3)  ·  fludarabine (3)  ·  midostaurin (3)  ·  Dasatinib (2)  ·  Diphenhydramine (2)  ·  Imatinib Mesylate (2)  ·  Methotrexate (2)  ·  Sodium Chloride (2)  ·  Tacrolimus (2)

Sponsors

M.D. Anderson Cancer Center (5)  ·  Fred Hutchinson Cancer Center (4)  ·  Novartis Pharmaceuticals (4)  ·  Blueprint Medicines Corporation (3)  ·  Jason Robert Gotlib (3)  ·  AB Science (2)  ·  Asan Medical Center (2)  ·  Cogent Biosciences, Inc. (2)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  City of Hope Medical Center (1)  ·  Federico II University (1)  ·  GT Biopharma, Inc. (1)  ·  Hospital Virgen de la Salud (1)  ·  JADO Technologies GmbH (1)  ·  Joseph Butterfield (1)

Countries

United States (30)  ·  Germany (12)  ·  Italy (11)  ·  France (10)  ·  Netherlands (9)  ·  Spain (9)  ·  Australia (7)  ·  Belgium (7)  ·  Norway (7)  ·  Poland (7)  ·  United Kingdom (7)  ·  Canada (6)  ·  Switzerland (6)  ·  Austria (5)  ·  Denmark (4)

Top investigators

Srdan Verstovsek, MD (3)  ·  Frank Siebenhaar, MD (2)  ·  Jason Gotlib (2)  ·  Kyoo H. Lee, MD (2)  ·  Olivier Lortholary, MD, PhD (2)  ·  Brenda Sandmaier (1)  ·  Charles L. Loprinzi, M.D. (1)  ·  David Maloney (1)  ·  David Miklos (1)  ·  Elizabeth C. Dees, MD (1)  ·  Hagop M Kantarjian, MD (1)  ·  Hirsh D Komarow, M.D. (1)  ·  Ibrahim Aldoss, MD (1)

Results publications

PMID 27355533, PMID 16775235, PMID 17715389, PMID 18327587, PMID 19451433, PMID 21098399, PMID 21108325, PMID 21523798, PMID 22563089, PMID 23547655, PMID 24057647, PMID 26002753, PMID 28744009, PMID 29890238, PMID 31350306, PMID 32437738, PMID 32499241, PMID 33049057, PMID 34663404, PMID 34873345, PMID 35640224, PMID 35790816, PMID 38320129, PMID 39649724, PMID 40529483, PMID 41244098, PMID 41604606, PMID 41690487

NIH funding

P30CA015704 (3), P01CA018029 (2), 2008 (1), 2017 (1), 2018 (1), N01CM62202 (1), P01CA049605 (1), P01CA078902 (1), P30CA015083 (1), P30CA124435 (1)